Release Date: 30 July 2024
Turkey has increasingly become a significant hub for cancer drug clinical trials, reflecting its strategic geographical position, advanced medical infrastructure, and robust healthcare system. The landscape of cancer drug...
Release Date: 29 July 2024
Antibody-drug conjugates (ADCs) have revolutionized cancer treatment by combining the targeting capabilities of antibodies with the cytotoxic power of chemotherapy. Delta-Like Ligand 3 (DLL3) has emerged as a promising ta...
Release Date: 29 July 2024
Delta-Like Ligand 3 (DLL3) has emerged as a key target for novel anti-cancer strategies, particularly in the treatment of aggressive malignancies such as small cell lung cancer (SCLC) and neuroendocrine tumors. The select...
Release Date: 29 July 2024
Immunotherapy has revolutionized cancer treatment, offering new hope for patients with aggressive malignancies. Delta-Like Ligand 3 (DLL3) has emerged as a promising target for immunotherapy, particularly in small cell lu...
Release Date: 29 July 2024
Claudin 18.2, a tight junction protein, has become a pioneering target in the development of targeted cancer therapies. Numerous clinical trials are underway to explore the efficacy and safety of Claudin 18.2-targeted tre...
Release Date: 29 July 2024
The development of Claudin 18.2 antibodies has marked a significant milestone in the field of targeted cancer therapy. Claudin 18.2, a tight junction protein, is overexpressed in several cancers, including gastric, pancre...
Release Date: 29 July 2024
The evaluation of safety and efficacy is paramount in the development of new cancer therapies. Claudin 18.2, a tight junction protein, has become a focal point in clinical trials aiming to target various cancers. This art...
Release Date: 29 July 2024
Advances in targeting CD70 for cancer treatment have led to the development of innovative therapies that offer improved specificity and efficacy. CD70, a member of the tumor necrosis factor (TNF) family, is selectively ex...
Release Date: 29 July 2024
CD70 and its ligand CD27 play crucial roles in cancer immunotherapy due to their involvement in immune regulation and tumor biology. CD70, a member of the tumor necrosis factor (TNF) family, is selectively expressed on va...
Release Date: 29 July 2024
CD70 has gained recognition as both a biomarker and therapeutic target in oncology due to its selective expression on various tumor cells and its involvement in tumor progression and immune evasion. As a member of the tum...
Release Date: 28 July 2024
Delta-Like Ligand 3 (DLL3) has emerged as both a biomarker and a therapeutic target in cancer treatment, particularly for aggressive malignancies such as small cell lung cancer (SCLC) and neuroendocrine tumors. The select...
Release Date: 28 July 2024
Resistance to cancer therapies is a significant challenge in oncology, often leading to treatment failure and disease progression. Delta-Like Ligand 3 (DLL3) inhibitors have shown promise in overcoming resistance mechanis...
Release Date: 28 July 2024
Delta-Like Ligand 3 (DLL3) antibody therapies are at the forefront of innovative cancer treatments, particularly for aggressive malignancies such as small cell lung cancer (SCLC) and neuroendocrine tumors. As research adv...
Release Date: 28 July 2024
Release Date: 28 July 2024
Recent advances in clinical trials targeting Claudin 18.2 have shown great promise for improving cancer treatment outcomes. Claudin 18.2, a protein expressed in various cancers such as gastric, pancreatic, and ovarian can...